Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

Glycosaminoglycan modification of NRP1 exon 4-skipping variant drives colorectal cancer metastasis via endosomal-exosomal trafficking

Producción científica: Articlerevisión exhaustiva

4 Citas (Scopus)

Resumen

Neuropilin-1 (NRP1) is a transmembrane glycoprotein that functions as a co-receptor with various cellular functions. Our previous studies identified the NRP1 exon 4-skipping (NRP1-ΔE4) splice variant as an aggressive metastasis driver by activating endosomal signals. Here, we demonstrate the critical role of glycosaminoglycan (GAG) modification in regulating NRP1-ΔE4's cellular trafficking and oncogenic activity. NRP1-ΔE4 undergoes constitutive internalization into endosomes and subsequent exosomal release from colorectal cancer (CRC) cells. Exosomal NRP1-ΔE4 enhances the migration and invasion of both donor and recipient CRC cells. Genetic or pharmacological inhibition of exosome secretion, or immunodepletion of exosomal NRP1-ΔE4, markedly reduces its metastatic potential. Notably, GAG modification at the O-glycosylation site Ser612 is essential for NRP1-ΔE4's endosomal trafficking and exosomal release. This modification also promotes the formation of a trimeric complex with Met and β1-integrin, leading to their co-internalization and accumulation in endosomes, which activates FAK signaling and drives CRC metastasis. These findings reveal GAG modification as a key regulatory process that governs the endosomal-exosomal trafficking of NRP1-ΔE4 to facilitate CRC cell dissemination.

Idioma originalEnglish
Número de artículo217683
PublicaciónCancer Letters
Volumen620
DOI
EstadoPublished - jun 28 2025

Nota bibliográfica

Publisher Copyright:
© 2025 Elsevier B.V.

Financiación

We thank Dali Qian (Electron Microscopy Center, University of Kentucky) for his technical assistance with the transmission electron microscopy analysis of exosomes. This work was supported in part by NIH grants R01CA175105 and R21ES031712, as well as by the UK Markey Cancer Center CCSG pilot grant (NIH P30CA177558) and start-up funds to Q.-B.S.

FinanciadoresNúmero del financiador
National Institutes of Health (NIH)R01CA175105, R21ES031712
University of Kentucky Markey Comprehensive Cancer CenterP30CA177558

    ODS de las Naciones Unidas

    Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

    1. Good health and well being
      Good health and well being

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Huella

    Profundice en los temas de investigación de 'Glycosaminoglycan modification of NRP1 exon 4-skipping variant drives colorectal cancer metastasis via endosomal-exosomal trafficking'. En conjunto forman una huella única.

    Citar esto